US2802005A
(en)
|
|
1957-08-06 |
|
S-eluorourace |
US729332A
(en)
*
|
1902-07-21 |
1903-05-26 |
Frank C Guss |
Animal catching and holding device.
|
US2885396A
(en)
|
1957-03-21 |
1959-05-05 |
Heidelberger Charles |
N-glycosides of 5-fluorouracil
|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
US3885035A
(en)
|
1972-04-05 |
1975-05-20 |
Sandoz Ag |
Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines
|
CH605550A5
(pt-PT)
|
1972-06-08 |
1978-09-29 |
Research Corp |
|
US3956495A
(en)
|
1973-10-30 |
1976-05-11 |
Eli Lilly And Company |
2,4-Diaminoquinazolines as antithrombotic agents
|
US3966936A
(en)
|
1974-02-21 |
1976-06-29 |
Pfizer Inc. |
Piperazino quinazoline bronchodilators
|
US4060615A
(en)
|
1976-02-18 |
1977-11-29 |
Mead Johnson & Company |
2-Piperazinyl-6,7-dimethoxyquinazolines
|
JPS6041077B2
(ja)
|
1976-09-06 |
1985-09-13 |
喜徳 喜谷 |
1,2‐ジアミノシクロヘキサン異性体のシス白金(2)錯体
|
JPS562968A
(en)
|
1979-06-21 |
1981-01-13 |
Mitsubishi Yuka Yakuhin Kk |
Novel pyrimidine derivative
|
US5260291A
(en)
|
1981-08-24 |
1993-11-09 |
Cancer Research Campaign Technology Limited |
Tetrazine derivatives
|
US4526988A
(en)
|
1983-03-10 |
1985-07-02 |
Eli Lilly And Company |
Difluoro antivirals and intermediate therefor
|
ATE92499T1
(de)
|
1984-12-04 |
1993-08-15 |
Lilly Co Eli |
Tumorbehandlung bei saeugetieren.
|
JPS6270A
(ja)
|
1985-03-07 |
1987-01-06 |
Sankyo Co Ltd |
シクロペンタ〔d〕ピリミジン誘導体
|
US5583024A
(en)
|
1985-12-02 |
1996-12-10 |
The Regents Of The University Of California |
Recombinant expression of Coleoptera luciferase
|
WO1987004928A1
(en)
|
1986-02-24 |
1987-08-27 |
Mitsui Petrochemical Industries, Ltd. |
Agents for treating neurophathy
|
FR2601675B1
(fr)
|
1986-07-17 |
1988-09-23 |
Rhone Poulenc Sante |
Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
|
US4889856A
(en)
|
1987-08-31 |
1989-12-26 |
Merck & Co., Inc. |
7,8-dihydro-4-(1-pierazinyl)-6H-thiopyrano-[3,2-d] pyrimidines as β-blockers
|
US4871739A
(en)
|
1987-01-21 |
1989-10-03 |
Merck & Co., Inc. |
Substituted 6H-7,8-dihydrothiapyrano(3,2-D)-pyrimidines as hyopglycemic agents
|
US4994464A
(en)
|
1987-08-31 |
1991-02-19 |
Merck & Co., Inc. |
Piperazinylpyrimidines as β-adrenergic receptor blockers
|
WO1990007926A1
(en)
|
1989-01-20 |
1990-07-26 |
Pfizer Inc. |
3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
|
US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
US20030206899A1
(en)
|
1991-03-29 |
2003-11-06 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
CA2103059C
(en)
|
1991-06-14 |
2005-03-22 |
Paul J. Carter |
Method for making humanized antibodies
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
US5714512A
(en)
|
1991-07-08 |
1998-02-03 |
Rhone-Poulenc Rorer, S.A. |
Compositions containing taxane derivatives
|
US5698582A
(en)
|
1991-07-08 |
1997-12-16 |
Rhone-Poulenc Rorer S.A. |
Compositions containing taxane derivatives
|
US5750561A
(en)
|
1991-07-08 |
1998-05-12 |
Rhone-Poulenc Rorer, S.A. |
Compositions containing taxane derivatives
|
US5604213A
(en)
|
1992-03-31 |
1997-02-18 |
British Technology Group Limited |
17-substituted steroids useful in cancer treatment
|
DK0664291T3
(da)
|
1992-10-05 |
2000-10-30 |
Ube Industries |
Pyrimidinforbindelse
|
HU221343B1
(en)
|
1992-10-28 |
2002-09-28 |
Genentech Inc |
Use of anti-vegf antibodies for the treatment of cancer
|
FR2698543B1
(fr)
|
1992-12-02 |
1994-12-30 |
Rhone Poulenc Rorer Sa |
Nouvelles compositions à base de taxoides.
|
EP0710654A4
(en)
|
1993-07-23 |
1996-08-28 |
Green Cross Corp |
TRIAZOLE DERIVATIVE AND ITS PHARMACEUTICAL USE
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
GB9416189D0
(en)
|
1994-08-10 |
1994-09-28 |
Merck Sharp & Dohme |
Therapeutic agents
|
ES2201112T3
(es)
|
1994-08-13 |
2004-03-16 |
Yuhan Corporation |
Nuevos derivados de pirimidina y procedimientos para su preparacion.
|
US5543523A
(en)
|
1994-11-15 |
1996-08-06 |
Regents Of The University Of Minnesota |
Method and intermediates for the synthesis of korupensamines
|
US5525625A
(en)
|
1995-01-24 |
1996-06-11 |
Warner-Lambert Company |
2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
|
IL117645A
(en)
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
JPH08336393A
(ja)
|
1995-04-13 |
1996-12-24 |
Mitsubishi Chem Corp |
光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
US7067664B1
(en)
|
1995-06-06 |
2006-06-27 |
Pfizer Inc. |
Corticotropin releasing factor antagonists
|
US7294332B2
(en)
|
1995-10-04 |
2007-11-13 |
Schering Corporation |
Combination therapy (temozolomide and α-IFN) for advanced cancer
|
ZA979961B
(en)
|
1996-11-15 |
1999-05-05 |
Lilly Co Eli |
5-HT1F agonists
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
DE69842174D1
(de)
|
1997-04-07 |
2011-04-21 |
Genentech Inc |
Verfahren zur Herstellung humanisierter Antikörper durch randomisierte Mutagenese
|
ES2273415T3
(es)
|
1997-04-07 |
2007-05-01 |
Genentech, Inc. |
Anticuerpos anti-vegf.
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
EP0993437B1
(en)
|
1997-07-01 |
2006-11-08 |
Warner-Lambert Company Llc |
2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
|
US6506798B1
(en)
|
1997-07-01 |
2003-01-14 |
Warner-Lambert Company |
4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
|
WO1999001426A1
(en)
|
1997-07-01 |
1999-01-14 |
Warner-Lambert Company |
4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
|
US6821963B2
(en)
|
1997-07-01 |
2004-11-23 |
Warner-Lambert Company |
4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
|
US6310060B1
(en)
|
1998-06-24 |
2001-10-30 |
Warner-Lambert Company |
2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
|
US6602677B1
(en)
|
1997-09-19 |
2003-08-05 |
Promega Corporation |
Thermostable luciferases and methods of production
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
EP1067123B1
(en)
|
1998-03-31 |
2011-01-19 |
Kyowa Hakko Kirin Co., Ltd. |
Nitrogenous heterocyclic compounds
|
DE19853278A1
(de)
|
1998-11-19 |
2000-05-25 |
Aventis Pharma Gmbh |
Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
HUP0104933A3
(en)
|
1999-01-07 |
2003-12-29 |
Warner Lambert Co |
Antiviral method using mek inhibitors
|
ATE292462T1
(de)
|
1999-01-07 |
2005-04-15 |
Warner Lambert Co |
Behandlung von asthma anhand von mek-inhibitoren
|
YU49401A
(sh)
|
1999-01-13 |
2004-07-15 |
Warner-Lambert Company |
Benzoheterocikli i njihova upotreba kao inhibitori mek
|
ES2252996T3
(es)
|
1999-01-13 |
2006-05-16 |
Warner-Lambert Company Llc |
Derivados de bencenosulfonamida y su uso como inhibidores de mek.
|
ATE311363T1
(de)
|
1999-01-13 |
2005-12-15 |
Warner Lambert Co |
Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
|
JP2002534446A
(ja)
|
1999-01-13 |
2002-10-15 |
ワーナー−ランバート・カンパニー |
4′ヘテロアリールジアリールアミン
|
CA2348236A1
(en)
|
1999-01-13 |
2000-07-20 |
Stephen Douglas Barrett |
4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
|
SK9822001A3
(en)
|
1999-01-13 |
2002-08-06 |
Warner Lambert Co |
1-heterocycle substituted diarylamines, pharmaceutical compositions based thereon and their use in therapy
|
US9534254B1
(en)
|
1999-02-02 |
2017-01-03 |
Abbott Molecular Inc. |
Patient stratification for cancer therapy based on genomic DNA microarray analysis
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
GB9910577D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
ATE377597T1
(de)
|
1999-07-09 |
2007-11-15 |
Glaxo Group Ltd |
Anilinochinazoline als protein-tyrosin- kinasehemmer
|
WO2001005390A2
(en)
|
1999-07-16 |
2001-01-25 |
Warner-Lambert Company |
Method for treating chronic pain using mek inhibitors
|
WO2001005393A2
(en)
|
1999-07-16 |
2001-01-25 |
Warner-Lambert Company |
Method for treating chronic pain using mek inhibitors
|
HUP0202623A3
(en)
|
1999-07-16 |
2003-03-28 |
Warner Lambert Co |
Method for treating chronic pain using mek inhibitors
|
AU5785900A
(en)
|
1999-07-16 |
2001-02-05 |
Warner-Lambert Company |
Method for treating chronic pain using mek inhibitors
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
CA2403017A1
(en)
|
2000-03-15 |
2001-09-20 |
Warner-Lambert Company |
5-amide substituted diarylamines as mex inhibitors
|
AU2001273071B2
(en)
|
2000-06-30 |
2005-09-08 |
Glaxo Group Limited |
Quinazoline ditosylate salt compounds
|
GEP20053496B
(en)
|
2000-07-19 |
2005-04-25 |
Warner Lambert Co |
Oxygenated Esters of 4-Iodo Phenylamino Benzhydroxamic Acids
|
SK2072003A3
(en)
|
2000-08-25 |
2004-01-08 |
Warner Lambert Co |
Process for making N-aryl-anthranilic acids and their derivatives
|
HUP0302173A2
(hu)
|
2000-09-15 |
2003-09-29 |
Vertex Pharmaceuticals Incorporated |
Protein kináz inhibitorokként alkalmazható pirazolvegyületek
|
AU2002210714A1
(en)
|
2000-11-02 |
2002-06-11 |
Astrazeneca Ab |
Substituted quinolines as antitumor agents
|
JP4458746B2
(ja)
|
2001-01-16 |
2010-04-28 |
グラクソ グループ リミテッド |
癌の治療方法
|
WO2002083139A1
(en)
|
2001-04-10 |
2002-10-24 |
Merck & Co., Inc. |
Inhibitors of akt activity
|
ES2301633T3
(es)
|
2001-04-30 |
2008-07-01 |
Glaxo Group Limited |
Pirimidinas condensadas como antagonistas del factor de liberacion de corticotropina (crf).
|
NZ518726A
(en)
|
2001-05-09 |
2004-06-25 |
Warner Lambert Co |
Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
|
AU2002336462A1
(en)
|
2001-09-06 |
2003-03-24 |
Millennium Pharmaceuticals, Inc. |
Piperazine and homopiperazine compounds
|
WO2003049678A2
(en)
|
2001-12-06 |
2003-06-19 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
JP4469179B2
(ja)
|
2002-01-23 |
2010-05-26 |
バイエル ファーマセチカル コーポレーション |
Rhoキナーゼ阻害剤としてのピリミジン誘導体
|
TW200306819A
(en)
|
2002-01-25 |
2003-12-01 |
Vertex Pharma |
Indazole compounds useful as protein kinase inhibitors
|
US7235537B2
(en)
|
2002-03-13 |
2007-06-26 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
AU2003220202A1
(en)
|
2002-03-13 |
2003-09-29 |
Array Biopharma, Inc |
N3 alkylated benzimidazole derivatives as mek inhibitors
|
NZ535158A
(en)
|
2002-03-13 |
2007-06-29 |
Array Biopharma Inc |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
JP4394961B2
(ja)
|
2002-04-08 |
2010-01-06 |
メルク エンド カムパニー インコーポレーテッド |
Akt活性の阻害剤としての融合キノキサリン誘導体
|
CA2480880C
(en)
|
2002-04-08 |
2011-03-22 |
Merck & Co., Inc. |
Inhibitors of akt activity
|
AU2003226250B2
(en)
|
2002-04-08 |
2007-08-16 |
Merck Sharp & Dohme Corp. |
Inhibitors of Akt activity
|
EP1496896A4
(en)
|
2002-04-08 |
2007-10-31 |
Merck & Co Inc |
AKT INHIBITORS EFFECT
|
CA2484968A1
(en)
|
2002-05-10 |
2003-11-20 |
Neurocrine Biosciences, Inc. |
Substituted piperazine as melanocortin receptors ligands
|
CA2501365C
(en)
|
2002-10-30 |
2011-05-31 |
Merck & Co., Inc. |
Inhibitors of akt activity
|
US20040102360A1
(en)
|
2002-10-30 |
2004-05-27 |
Barnett Stanley F. |
Combination therapy
|
WO2004045617A1
(en)
|
2002-11-15 |
2004-06-03 |
Warner-Lambert Company Llc |
Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
|
CA2502970A1
(en)
|
2002-11-28 |
2004-06-10 |
Schering Aktiengesellschaft |
Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
|
GB0308208D0
(en)
|
2003-04-09 |
2003-05-14 |
Glaxo Group Ltd |
Chemical compounds
|
WO2004096130A2
(en)
|
2003-04-24 |
2004-11-11 |
Merck & Co., Inc. |
Inhibitors of akt activity
|
CA2526085A1
(en)
|
2003-05-30 |
2005-01-06 |
Genentech, Inc. |
Treatment with anti-vegf antibodies
|
EP1646615B1
(en)
|
2003-06-06 |
2009-08-26 |
Vertex Pharmaceuticals Incorporated |
Pyrimidine derivatives as modulators of atp-binding cassette transporters
|
TW200523262A
(en)
|
2003-07-29 |
2005-07-16 |
Smithkline Beecham Corp |
Inhibitors of AKT activity
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
PE20050355A1
(es)
|
2003-08-05 |
2005-05-16 |
Vertex Pharma |
Composiciones referidas a inhibidores de canales ionicos regulados por voltaje
|
ES2293317T3
(es)
|
2003-08-12 |
2008-03-16 |
F. Hoffmann-La Roche Ag |
Derivados de tetrahidroquinazolina com antagonistas de cfr.
|
BRPI0414238A
(pt)
|
2003-09-09 |
2006-10-31 |
Ono Pharmaceutical Co |
antagonistas de crf e compostos heterobicìclicos
|
WO2005039564A1
(en)
|
2003-10-02 |
2005-05-06 |
Vertex Pharmaceuticals Incorporated |
Phthalimide compounds useful as protein kinase inhibitors
|
AU2004283148A1
(en)
|
2003-10-21 |
2005-05-06 |
Warner-Lambert Company Llc |
Polymorphic form of N-[(R)-2,3-Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
|
CN1882347A
(zh)
|
2003-11-21 |
2006-12-20 |
阿雷生物药品公司 |
Akt蛋白激酶抑制剂
|
PT1696920E
(pt)
|
2003-12-19 |
2015-01-14 |
Plexxikon Inc |
Compostos e métodos para o desenvolvimento de moduladores de ret
|
EP1737472B1
(en)
|
2004-03-29 |
2014-08-13 |
University Of South Florida |
Effective treatment of tumors and cancer with triciribine
|
CA2563699C
(en)
|
2004-04-23 |
2014-03-25 |
Exelixis, Inc. |
Kinase modulators and method of use
|
ATE464303T1
(de)
|
2004-04-28 |
2010-04-15 |
Vertex Pharma |
Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
|
US20060009360A1
(en)
|
2004-06-25 |
2006-01-12 |
Robert Pifer |
New adjuvant composition
|
ATE434614T1
(de)
|
2004-06-28 |
2009-07-15 |
Bayer Schering Pharma Ag |
4,6-disubstitutierte pyrimidine und deren verwendung als proteinkinase-hemmer
|
US20060025074A1
(en)
|
2004-07-30 |
2006-02-02 |
Chih-Ming Liang |
Bluetooth-based headset
|
TWM266655U
(en)
|
2004-09-23 |
2005-06-01 |
Blueexpert Technology Corp |
Bluetooth earphone device capable of wirelessly receiving and transmitting stereo sound signal and digital information signal
|
TW200621257A
(en)
|
2004-10-20 |
2006-07-01 |
Astellas Pharma Inc |
Pyrimidine derivative fused with nonaromatic ring
|
UY29177A1
(es)
|
2004-10-25 |
2006-05-31 |
Astex Therapeutics Ltd |
Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
|
US7994172B2
(en)
|
2004-12-28 |
2011-08-09 |
Exelixis, Inc. |
[1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
|
JP2008531542A
(ja)
|
2005-02-24 |
2008-08-14 |
ファイザー・プロダクツ・インク |
抗癌剤として有用な二環式複素芳香族誘導体
|
WO2006094230A2
(en)
|
2005-03-03 |
2006-09-08 |
The Burnham Institute For Medical Research |
Screening methods for protein kinase b inhibitors employing virtual docking approaches and compounds and compositions discovered thereby
|
US7709517B2
(en)
|
2005-05-13 |
2010-05-04 |
The Regents Of The University Of California |
Diarylhydantoin compounds
|
MX2007014619A
(es)
|
2005-05-20 |
2009-02-13 |
Vertex Pharma |
Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
|
UY29610A1
(es)
|
2005-06-21 |
2007-01-31 |
Cancer Rec Tech Ltd |
Aril-alquilaminas y heteroaril-alquilaminas como inhibidores de la quinasa proteínica
|
RS52010B
(en)
|
2005-06-22 |
2012-04-30 |
Plexxikon Inc. |
DERIVATI PIROLO [2, 3-B] PIRIDINA KAO INHIBITORI PROTEIN KINAZE
|
JP5129143B2
(ja)
|
2005-10-07 |
2013-01-23 |
エグゼリクシス, インコーポレイテッド |
Mekインヒビターおよびその使用方法
|
US20080004295A1
(en)
|
2005-10-13 |
2008-01-03 |
Gore Paul M |
Novel compounds
|
WO2007060691A2
(en)
|
2005-11-23 |
2007-05-31 |
Natco Pharma Limited |
A novel process for the preparation of erlotinib
|
WO2007077961A2
(en)
|
2005-12-28 |
2007-07-12 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands
|
KR101028979B1
(ko)
|
2006-03-02 |
2011-04-12 |
닛본 세이고 가부시끼가이샤 |
토크 센서
|
EP2013206A1
(en)
|
2006-04-25 |
2009-01-14 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
KR20090024834A
(ko)
|
2006-07-05 |
2009-03-09 |
인터뮨, 인크. |
C형 간염 바이러스 복제의 신규 억제제
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
UA95641C2
(en)
*
|
2006-07-06 |
2011-08-25 |
Эррей Биофарма Инк. |
Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
|
EA016076B1
(ru)
|
2006-07-06 |
2012-01-30 |
Глэксо Груп Лимитед |
Замещенные n-фенилметил-5-оксопролин-2-амиды в качестве антагонистов р2х7-рецептора и способы их применения
|
CA2656618C
(en)
|
2006-07-06 |
2014-08-26 |
Array Biopharma Inc. |
Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
|
US7910747B2
(en)
|
2006-07-06 |
2011-03-22 |
Bristol-Myers Squibb Company |
Phosphonate and phosphinate pyrazolylamide glucokinase activators
|
EP2054418B1
(en)
|
2006-07-06 |
2011-11-09 |
Array Biopharma Inc. |
Dihydrothieno pyrimidines as akt protein kinase inhibitors
|
GB0613518D0
(en)
|
2006-07-06 |
2006-08-16 |
Phytopharm Plc |
Chemical compounds
|
TW200808325A
(en)
|
2006-07-06 |
2008-02-16 |
Astrazeneca Ab |
Novel compounds
|
WO2008012635A2
(en)
|
2006-07-26 |
2008-01-31 |
Pfizer Products Inc. |
Amine derivatives useful as anticancer agents
|
KR20090047509A
(ko)
|
2006-08-04 |
2009-05-12 |
다케다 야쿠힌 고교 가부시키가이샤 |
융합 헤테로시클릭 유도체 및 이의 용도
|
HUE054495T2
(hu)
|
2006-08-25 |
2021-09-28 |
Janssen Oncology Inc |
Rák kezelésére szolgáló készítmény
|
US8828451B2
(en)
|
2006-10-04 |
2014-09-09 |
University Of South Florida |
Akt sensitization of cancer cells
|
CN101332301A
(zh)
*
|
2007-06-26 |
2008-12-31 |
南京医科大学 |
一种抗肿瘤组合物及其应用
|
BRPI0815563A2
(pt)
|
2007-07-12 |
2015-02-18 |
Univ South Florida |
Inibidores de akt/pkb com atividade antitumoral
|
CN101801188A
(zh)
*
|
2007-07-12 |
2010-08-11 |
特拉加拉医药品公司 |
治疗癌症、肿瘤和肿瘤相关性疾病的方法和组合物
|
US8137919B2
(en)
*
|
2008-04-10 |
2012-03-20 |
Montefiore Medical Center |
Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib
|
JP5579715B2
(ja)
*
|
2008-07-29 |
2014-08-27 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
cdk阻害剤および抗悪性腫瘍剤を含む治療用組合せ
|
RU2473549C2
(ru)
|
2008-07-31 |
2013-01-27 |
Дженентек, Инк. |
Пиримидиновые соединения, композиции и способы применения
|
EP3617330B1
(en)
*
|
2011-04-01 |
2023-12-27 |
Genentech, Inc. |
Biomarkers for predicting sensitivity to cancer treatments
|
CN103635192B
(zh)
|
2011-04-01 |
2017-07-04 |
基因泰克公司 |
Akt抑制剂化合物和化疗剂的组合以及使用方法
|